RHOA and breast carcinoma: We noted that the ARHGEF1 i.p. generated from lysates of breast-cancer PDX treated with cortactin siRNA had less capacity to generate activated RhoA than the ARHGEF1 i.p. of PDX treated with control, nonspecific siRNA (Supplementary Fig. 9d).